



NEWS RELEASE

FOR IMMEDIATE RELEASE

Contact:

Sheryl Seapy, Pure Communications
(949) 608-0841

XDx CEO Pierre Cassigneul to Speak at New Frontiers in Personalized Medicine Conference in Washington, D.C.

BRISBANE, Calif., January 3, 2011 – XDx, Inc., a molecular diagnostics company focused on non-invasive gene expression-based tests for the monitoring of transplant rejection and autoimmune diseases, announced today that Pierre G. Cassigneul, XDx's president and CEO, will discuss current clinical applications of personalized approaches to cardiovascular medicine at a forthcoming conference organized by the Personalized Medicine Coalition in collaboration with the American College of Cardiology, the American Medical Association, the National Heart Lung and Blood Institute and the Cheney Cardiovascular Institute at The George Washington University.

The conference, *New Frontiers in Personalized Medicine: Cardiovascular Research & Clinical Care* will be held January 6, 2011 at The George Washington University and will bring together academic, industry and government leaders to address the critical issues facing the future of cardiovascular research and clinical care in science, business, education and policy.

"It's critical to help the research and medical community appreciate the applications of personalized medicine to cardiovascular disease—currently the leading cause of death in the United States," said Mr. Cassigneul. "New technologies and understandings of variation among patients are helping to reshape cardiovascular care."

A special report in *Nature* noted that, after oncology, cardiology holds the most promise in personalizing, and therefore improving, therapies.

"Improving outcomes, increasing efficacy and decreasing adverse events is critical," said Edward Abrahams, Ph.D., president of the Personalized Medicine Coalition.

"Cardiovascular disease is the number one cause of death in the United States and poised to become the leading cause of death globally."

Personalized Medicine—Opportunity to Transform Patient Care

The Personalized Medicine Coalition (PMC) was launched in 2004 in an effort to educate the public and policymakers, and to promote new ways of thinking about healthcare with the mission of advancing personalized medicine as a viable solution to the challenges of efficacy, safety and cost. Today, PMC represents a broad spectrum of



NEWS RELEASE

nearly 200 academic, industry, patient, provider and payer communities, as the organization seeks to advance the understanding and adoption of personalized medicine concepts and products for the benefit of patients. More information on the *New Frontiers in Personalized Medicine: Cardiovascular Research & Clinical Care* conference is available at <http://www.personalizedmedicinecoalition.org/events/cardiovascular2011>.

“The Personalized Medicine Coalition has organized a superb program with an impressive lineup of speakers and topics,” said Eric Topol, M.D., director of the Scripps Translational Science Institute and chief academic officer for Scripps Health. “The discussions and exchange of ideas should help catapult individualized cardiovascular medicine forward – which is desperately needed.”

About XDx

XDx, Inc., based in Brisbane, California, is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression-based tests for the monitoring of transplant rejection and autoimmune diseases. The company has developed AlloMap Molecular Expression Testing, an FDA-cleared test, which provides transplant physicians with a tool to aid in the determination of the probability of acute cellular rejection for post-cardiac transplant patient management. Some of the AlloMap technology developed and implemented by XDx in heart transplant patient management may be applicable to other conditions that involve transplant rejection and diseases that affect the immune system. XDx's non-invasive technology offers the potential to decrease healthcare costs and improve the quality of life for patients with a variety of life-threatening or life-altering immune-mediated diseases. For more information, please visit www.xdx.com.

###